Chipscreen Biosciences Out-Licenses Taiwanese Rights for Cancer Drug to GNT Biotech and Medicals Corporation
by Richard Daverman, PhD
October 11, 2013 -- Shenzhen Chipscreen Biosciences has out-licensed Taiwanese rights for a cancer drug candidate, Chidamide, to GNT Biotech and Medicals of Taiwan. Chidamide is an oral, selective histone deacetylase (HDAC) inhibitor that is currently being tested in a China Phase II clinical trial. Financial details of the agreement were not disclosed. More details....
Help employers find you! Check out all the jobs and post your resume.